Results of gammopathy monitoring before onset, at onset, and during treatment of LPD
| Patient . | Before onset of LPD . | At onset of LPD . | LPD treatment . | Outcome of LPD treatment . | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| GP at OLT* . | GP 4 mo after OLT*,† . | GP* . | Mean total Ig (g/L) . | GP components . | Type of treatment . | GP at end of treatment* . | Imaging at end of treatment* . | Outcome . | Time after LPD (mo) . | |
| 1 | 0 | NA | 0 | 17.2 | 0 | IS, reOLT | 0 | 0 | Remission | 1 |
| 2 | 0 | NA | 0 | 31.3 | 0 | IS | 0 | 0 | Remission | 4 |
| 3 | 0 | NA | 1 | 11.3 | 1 IgMλ + 2 IgMκ | IS | 0 | 0 | Remission | 2 |
| 4 | 0 | NA | 1 | 10.8 | 1 IgMλ | IS | 0 | 0 | Remission | 3 |
| 5 | 1 | NA | 1‡ | 10.9 | 2 IgGλ + 1 IgGκ | IS | 0.5 | 0 | Remission | 6 |
| 6 | 0 | NA | 1 | 10.5 | 1 IgMλ + 3 IgGκ | IS, anti–IL-6, reOLT | 0 | 0 | Remission | 10 |
| 7 | 0 | NA | 1 | 7.0 | 1 IgGλ + 3 IgGκ | IS, CT, anti-CD20 | 0 | 0 | Remission | 6 |
| 8 | 0 | NA | 1 | 7.7 | 2 IgGλ + 1 IgGκ + 1 IgMκ | IS, CT, anti-CD20 | 0 | 0 | Remission | 4 |
| 9 | 0 | NA | 1 | 12.0 | 3 IgGλ | IS, CT | 1 | 1 | Death | 18 |
| 10 | 0 | 1 | 1 | 23.0 | 2 IgGκ | IS, RT | 1 | 1 | Death | 8 |
| 11 | 0 | 1 | 1‡ | 9.3 | 2 IgGλ + 1 IgGκ | IS, CT, anti-CD20 | 1 | 1 | No remission | 8 |
| 12 | 0 | 1 | 1 | 11.3 | 1 IgMλ + 3 IgGκ | IS, anti-CD20 | 0.5 | 1 | Death | 4 |
| 13 | 1 | 0 | 0 | 9.6 | 0 | IS, reOLT | 0 | 0 | Remission | 1 |
| 14 | 0 | 1 | 1 | 9.8 | 1 IgMκ | IS, CT | 0 | 0 | Remission | 7 |
| 15 | 0 | 1 | 1 | 14.5 | 1 IgGκ | IS, CT, surgery | 0 | 0 | Remission | 8 |
| 16 | 0 | 0 | 1 | 3.5 | Free λ | IS, CT | 0 | 0 | Remission | 5 |
| 17 | 0 | 0 | 1 | 9.2 | 1 IgMκ | IS, CT | 1 | 1 | Death | 7 |
| 18 | 0 | 1 | 1 | 12.5 | 1 IgGκ | IS, CT | 0 | 0 | Remission | 5 |
| 19 | 0 | 1 | 1 | 15.6 | 1 IgGλ + 1 IgGκ | IS, anti-CD20 | 0 | 1 | Improvement | 3 |
| 20 | 0 | 1 | 1 | 13.0 | 2 IgGκ | IS, CT | 1 | 1 | Death | 5 |
| 21 | 1 | 1 | 1‡ | 8.5 | 2 IgGκ | IS, anti-CD20 | 1 | 1 | Improvement | 8 |
| Patient . | Before onset of LPD . | At onset of LPD . | LPD treatment . | Outcome of LPD treatment . | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| GP at OLT* . | GP 4 mo after OLT*,† . | GP* . | Mean total Ig (g/L) . | GP components . | Type of treatment . | GP at end of treatment* . | Imaging at end of treatment* . | Outcome . | Time after LPD (mo) . | |
| 1 | 0 | NA | 0 | 17.2 | 0 | IS, reOLT | 0 | 0 | Remission | 1 |
| 2 | 0 | NA | 0 | 31.3 | 0 | IS | 0 | 0 | Remission | 4 |
| 3 | 0 | NA | 1 | 11.3 | 1 IgMλ + 2 IgMκ | IS | 0 | 0 | Remission | 2 |
| 4 | 0 | NA | 1 | 10.8 | 1 IgMλ | IS | 0 | 0 | Remission | 3 |
| 5 | 1 | NA | 1‡ | 10.9 | 2 IgGλ + 1 IgGκ | IS | 0.5 | 0 | Remission | 6 |
| 6 | 0 | NA | 1 | 10.5 | 1 IgMλ + 3 IgGκ | IS, anti–IL-6, reOLT | 0 | 0 | Remission | 10 |
| 7 | 0 | NA | 1 | 7.0 | 1 IgGλ + 3 IgGκ | IS, CT, anti-CD20 | 0 | 0 | Remission | 6 |
| 8 | 0 | NA | 1 | 7.7 | 2 IgGλ + 1 IgGκ + 1 IgMκ | IS, CT, anti-CD20 | 0 | 0 | Remission | 4 |
| 9 | 0 | NA | 1 | 12.0 | 3 IgGλ | IS, CT | 1 | 1 | Death | 18 |
| 10 | 0 | 1 | 1 | 23.0 | 2 IgGκ | IS, RT | 1 | 1 | Death | 8 |
| 11 | 0 | 1 | 1‡ | 9.3 | 2 IgGλ + 1 IgGκ | IS, CT, anti-CD20 | 1 | 1 | No remission | 8 |
| 12 | 0 | 1 | 1 | 11.3 | 1 IgMλ + 3 IgGκ | IS, anti-CD20 | 0.5 | 1 | Death | 4 |
| 13 | 1 | 0 | 0 | 9.6 | 0 | IS, reOLT | 0 | 0 | Remission | 1 |
| 14 | 0 | 1 | 1 | 9.8 | 1 IgMκ | IS, CT | 0 | 0 | Remission | 7 |
| 15 | 0 | 1 | 1 | 14.5 | 1 IgGκ | IS, CT, surgery | 0 | 0 | Remission | 8 |
| 16 | 0 | 0 | 1 | 3.5 | Free λ | IS, CT | 0 | 0 | Remission | 5 |
| 17 | 0 | 0 | 1 | 9.2 | 1 IgMκ | IS, CT | 1 | 1 | Death | 7 |
| 18 | 0 | 1 | 1 | 12.5 | 1 IgGκ | IS, CT | 0 | 0 | Remission | 5 |
| 19 | 0 | 1 | 1 | 15.6 | 1 IgGλ + 1 IgGκ | IS, anti-CD20 | 0 | 1 | Improvement | 3 |
| 20 | 0 | 1 | 1 | 13.0 | 2 IgGκ | IS, CT | 1 | 1 | Death | 5 |
| 21 | 1 | 1 | 1‡ | 8.5 | 2 IgGκ | IS, anti-CD20 | 1 | 1 | Improvement | 8 |
GP indicates gammopathy; NA, nonapplicable; IS, reduction in immunosuppression 1; reOLT, more than 1 OLT; CT, chemotherapy; IL-6, interleukin-6; and RT, radiotherapy.
0, normal results on serum protein electrophoresis or imaging; and 1, presence of GP and GP 4 represents the last SPE in these patients.
In patients 1 to 13, LPD developed in the first year after OLT; in patients 14 to 21, LPD developed more than 2 years after OLT or abnormal imaging.
Appearance of a new immunoglobulin component.